Taken together our preclinical results show that a newly developed CXCR4 antagonist Pep R is able to improve standard therapy efficacy targeting cell growth and mesenchymal transition, endorsing further clinical studies for association of CXCR4 antagonists plus standard therapy in colorectal cancer. Here, CXCR4 is linked to colorectal cancer.